These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10684748)

  • 1. A randomized controlled trial of a clinic-based support staff intervention to increase the rate of fecal occult blood test ordering.
    Thompson NJ; Boyko EJ; Dominitz JA; Belcher DW; Chesebro BB; Stephens LM; Chapko MK
    Prev Med; 2000 Mar; 30(3):244-51. PubMed ID: 10684748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
    Sharma VK; Corder FA; Fancher J; Howden CW
    Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does use of the Coloscreen Self-Test improve patient compliance with fecal occult blood screening?
    Park SI; Saxe JC; Weesner RE
    Am J Gastroenterol; 1993 Sep; 88(9):1391-4. PubMed ID: 8362837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing.
    Stokamer CL; Tenner CT; Chaudhuri J; Vazquez E; Bini EJ
    J Gen Intern Med; 2005 Mar; 20(3):278-82. PubMed ID: 15836533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for colorectal cancer.
    Mandel JS
    Curr Opin Gen Surg; 1994; ():79-84. PubMed ID: 7584018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial.
    Hoffman RM; Steel S; Yee EF; Massie L; Schrader RM; Murata GH
    Prev Med; 2010; 50(5-6):297-9. PubMed ID: 20307568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal occult blood test performance indicators in warfarin-treated patients.
    Kershenbaum A; Lavi I; Rennert G; Almog R
    Dis Colon Rectum; 2010 Feb; 53(2):224-9. PubMed ID: 20087099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance.
    Sharma VK; Corder FA; Raufman JP; Sharma P; Fennerty MB; Howden CW
    Am J Gastroenterol; 2000 Aug; 95(8):2068-73. PubMed ID: 10950059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fecal occult blood test and mass screening for colorectal cancer].
    Saito H; Soma Y; Kawaguchi H
    Gan To Kagaku Ryoho; 1991 Oct; 18(13):2232-40. PubMed ID: 1929443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristics of colorectal carcinomas detected by mass screening].
    Kikkawa N; Tsuchiya Y; Matsui S; Murai M; Yamamoto H; Matsui K
    Gan No Rinsho; 1989 Jul; 35(8):923-6. PubMed ID: 2746866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving colorectal cancer screening in a medical residents' primary care clinic.
    Struewing JP; Pape DM; Snow DA
    Am J Prev Med; 1991; 7(2):75-81. PubMed ID: 1910891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of family physicians in increasing annual fecal occult blood test screening coverage: a prospective intervention study.
    Vinker S; Nakar S; Rosenberg E; Kitai E
    Isr Med Assoc J; 2002 Jun; 4(6):424-5. PubMed ID: 12073414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population colorectal cancer screening with fecal occult blood test.
    Rennert G; Rennert HS; Miron E; Peterburg Y
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mailings timed to patients' appointments: a controlled trial of fecal occult blood test cards.
    Goldberg D; Schiff GD; McNutt R; Furumoto-Dawson A; Hammerman M; Hoffman A
    Am J Prev Med; 2004 Jun; 26(5):431-5. PubMed ID: 15165660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A provider intervention to improve colorectal cancer screening in county health centers.
    Lane DS; Messina CR; Cavanagh MF; Chen JJ
    Med Care; 2008 Sep; 46(9 Suppl 1):S109-16. PubMed ID: 18725822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening.
    Myers RE; Sifri R; Hyslop T; Rosenthal M; Vernon SW; Cocroft J; Wolf T; Andrel J; Wender R
    Cancer; 2007 Nov; 110(9):2083-91. PubMed ID: 17893869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.